Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
(Abstracted from Lancet 2025;405(10496):2205–2216) Deaths related to ovarian cancer were estimated at 207,000 in 2020 across the globe. An approximate 70% of patients have relapses of the disease after platinum-based chemotherapy as they develop resistance to the treatment; platinum-resistant ovarian cancer can be treated with nonplatinum chemotherapy with or without bevacizumab.
Authors
- Laurence Gladieff (ORCID: https://orcid.org/0000-0002-6980-9719)
- Grazia Artioli
- Mariana Scaranti (ORCID: https://orcid.org/0000-0001-7713-0100)
- Adrian M. Jubb
- Boglárka Balázs
- Alix Devaux (ORCID: https://orcid.org/0009-0000-0320-1850)
- David M. O’Malley (ORCID: https://orcid.org/0000-0002-2828-0177)
- Aknar Calabrich (ORCID: https://orcid.org/0000-0002-0641-5683)
- Andrew R. Clamp (ORCID: https://orcid.org/0000-0002-4200-0186)
- Giuseppe Luigi Banna (ORCID: https://orcid.org/0000-0003-0764-3650)
- Cristina Churruca (ORCID: https://orcid.org/0009-0009-2206-9600)
- Andrea Bagaméri (ORCID: https://orcid.org/0009-0007-5519-2598)
- Giuseppa Scandurra (ORCID: https://orcid.org/0000-0001-8025-581X)
- Brian M. Slomovitz (ORCID: https://orcid.org/0000-0002-7241-3096)
- Sachin Gopalkrishna Pai (ORCID: https://orcid.org/0000-0002-6755-3895)
- Connie I. Diakos (ORCID: https://orcid.org/0000-0002-8877-3440)
- Jae‐Weon Kim (ORCID: https://orcid.org/0000-0003-1835-9436)
- Lubomir Bodnar (ORCID: https://orcid.org/0000-0001-8548-8778)
- Iulia Cristina Tudor (ORCID: https://orcid.org/0000-0002-4229-2940)
- Hristina I. Pashova (ORCID: https://orcid.org/0000-0003-2297-1652)
- Aliza Leiser
- Sokbom Kang (ORCID: https://orcid.org/0000-0002-8428-9555)
- Ignace Vergote (ORCID: https://orcid.org/0000-0002-7589-8981)
- Chiara Cassani (ORCID: https://orcid.org/0000-0002-8055-5086)
- Alexander Babatunde Olawaiye (ORCID: https://orcid.org/0000-0002-2833-9255)
- Domenica Lorusso (ORCID: https://orcid.org/0000-0003-0981-0598)
- Linda Mileshkin (ORCID: https://orcid.org/0000-0001-6826-6014)
- Michael McCollum (ORCID: https://orcid.org/0009-0003-3010-3537)
- Ana Oaknin (ORCID: https://orcid.org/0000-0002-3592-7194)
- Emilie Kaczmarek (ORCID: https://orcid.org/0000-0002-2633-3773)
- Lucy Gilbert (ORCID: https://orcid.org/0000-0001-8605-5472)
- Shibani Nicum (ORCID: https://orcid.org/0000-0003-1125-405X)
- Benoît You (ORCID: https://orcid.org/0000-0002-3177-8857)
- Bradley Monk (ORCID: https://orcid.org/0000-0002-0680-3184)
- Toon Van Gorp (ORCID: https://orcid.org/0000-0002-2564-721X)
- Gabriel Garbaos
- Yong Jae Lee (ORCID: https://orcid.org/0000-0003-0297-3116)
- Vanda Salutari (ORCID: https://orcid.org/0000-0002-9420-7146)
- C. McClung (ORCID: https://orcid.org/0000-0002-9194-0617)
- Nicoletta Colombo (ORCID: https://orcid.org/0000-0003-2225-715X)
- Elizabeth Hopp (ORCID: https://orcid.org/0000-0002-0577-0501)
- Byoung-Gie Kim
- Amanda Kesner-Hays
- Helena De La Creva
Publication Details
- Journal
- Obstetrical & Gynecological Survey
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1097/01.ogx.0001169628.43305.4c
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00